他汀类使用与HIV感染者严重细菌感染风险:ANRS CO3阿基坦队列2000-2018年前瞻性研究
该研究基于ANRS CO3阿基坦前瞻性队列2000-2018年数据,纳入至少两次随访的HIV感染者,评估他汀类使用对首次严重细菌感染(SBI,住院≥48小时或死亡)的影响。调整指征偏倚和时间依赖混杂后,他汀类使用与SBI风险无关(HR=0.97;95%CI:0.75-1.25),对肺炎风险结果相似,敏感性分析一致。
要点
- 在他汀类使用者中未观察到严重细菌感染风险降低(HR=0.97;95%CI:0.75-1.25)。
- 他汀类对肺炎风险的影响与总体SBI结果相似,敏感性分析一致。
- 该HIV队列随访18年、严重感染风险高,仍未发现他汀类的保护效应。
核心结论
- 在随访18年、严重感染风险高的HIV感染者大型队列中,他汀类使用对严重细菌感染或肺炎的发生风险均无影响。
研究设计与样本
- 主要终点为首次导致住院≥48小时或死亡的细菌感染;他汀暴露在随访中更新,采用边际Cox结构模型处理指征偏倚和时间依赖混杂,并开展多项敏感性分析。
主要发现
- 首次严重细菌感染总发生率为12.4/1000人年。
- 以治疗开始后全程使用他汀类分析,未显示对严重细菌感染发生的影响(HR=0.97;95%CI:0.75-1.25)。
- 他汀类对肺炎风险的影响与总体严重细菌感染结果相似,所有敏感性分析结果一致。
临床怎么用
- 对于HIV感染者,不应基于预防严重细菌感染的预期而处方他汀类;他汀类使用应依据其常规心血管等适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bacterial infections remain one of the main causes of morbidity and death in people living with HIV (PLHIV) in the most recent years. Several studies have demonstrated a protective effect of statins in the primary prevention of bacterial infections in other immunocompromised populations, but this effect remains controversial. The objective of this study was to evaluate the effect of statin use on the occurrence of a first episode of severe bacterial infection (SBI) in PLHIV in the ANRS CO3 Aquitaine cohort between 2000 and 2018. METHODS: All individuals included in the prospective ANRS CO3 Aquitaine cohort who had at least two follow-up visits between 2000 and 2018 were included. The primary endpoint was the occurrence of a first episode of bacterial infection leading to hospitalization of ≥48 hours or death. Statin exposure was updated during follow-up. Marginal Cox structural models were developed to consider the potential indication bias and time-dependent confusion. Numerous sensitivity analyses were carried out. RESULTS: In this study 51 658 person-years were followed. The overall incidence of a first episode of SBI was 12.4/1000 person-years. No effect of statins on the occurrence of SBI was demonstrated when subjects were considered on statins throughout their follow-up after treatment initiation (HR = 0.97; 95%CI: 0.75-1.25). The results were similar for the effect of statins on the risk of pneumonia and for all sensitivity analyses. CONCLUSION: In this large cohort of PLHIV with 18 years of follow-up and a high risk of severe infections, we found no effect of statins on the risk of occurrence of SBI or pneumonia.
引用
- Teruel E, Vandenhende MA, Neau D, et al. Statin use and risk of severe bacterial infection in a population living with HIV: prospective cohort study of the ANRS CO3 Aquitaine Cohort 2000-2018. Clin Microbiol Infect. 2020. PMID: 33276140. doi:10.1016/j.cmi.2020.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。